Invasive aspergillosis caused by Aspergillus terreus: An emerging opportunistic infection with poor outcome independent of azole therapy

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 11, 2014, Pages 3148-3155

  Hachem, Ray ^a   Gomes, Marisa Zenaide Ribeiro ^a   El Helou, Gilbert ^a   El Zakhem, Aline ^a   Kassis, Christelle ^b   Ramos, Elizabeth ^b   Jiang, Ying ^a   Chaftari, Anne Marie ^a   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

A. terreus; Haematological malignancy; IA

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; PYRROLE; STEROID; TACROLIMUS; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL THERAPY; ARTICLE; ASPERGILLUS NIDULANS; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR; CHILD; CLINICAL FEATURE; CLINICAL OUTCOME; DYSPNEA; EUROTIUM HERBARIORUM; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INVASIVE ASPERGILLOSIS; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ASPERGILLOSIS; ASPERGILLUS; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; ISOLATION AND PURIFICATION; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; AZOLES; CHILD; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924948116     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku241     Document Type: Article

References (41)

1. Nicolle MC, Benet T, Thiebaut A et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica 2011; 96: 1685-91.
2. Graf K, Khani SM, Ott E et al. Five-years surveillance of invasive aspergillosis in a university hospital. BMC Infect Dis 2011; 11: 163.
3. Lewis RE, Cahyame-Zuniga L, Leventakos K et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 2013; 56: 638-45.
4. Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
5. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
6. Salmeron G, Porcher R, Bergeron A et al. Persistent poor long-term prognosis of allogeneic hematopoietic stem cell transplant recipients surviving invasive aspergillosis. Haematologica 2012; 97: 1357-63.
7. Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 644-50.
8. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100.
9. Steinbach WJ, Marr KA, Anaissie EJ et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012; 65: 453-64.
10. Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: 862-70.
11. Iwen PC, Reed EC, Armitage JO et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol 1993; 14: 131-9.
12. Iwen PC, Rupp ME, Langnas AN et al. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 1998; 26: 1092-7.
13. Ruping MJ, Gerlach S, Fischer G et al. Environmental and clinical epidemiology of Aspergillus terreus: data from a prospective surveillance study. J Hospital Infect 2011; 78: 226-30.
14. Snelders E, Camps SM, Karawajczyk A et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 2012; 7: e31801.
15. van der Linden JW, Camps SM, Kampinga GA et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57: 513-20.
16. Lass-Florl C, Grif K, Kontoyiannis DP. Molecular typing of Aspergillus terreus isolates collected in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity. J Clin Microbiol 2007; 45: 2686-90.
17. Arendrup MC, Jensen RH, Grif K et al. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis 2012; 206: 981-5.
18. Hachem RY, Kontoyiannis DP, Boktour MR et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594-600.
19. Moore CK, Hellreich MA, Coblentz CL et al. Aspergillus terreus as a cause of invasive pulmonary aspergillosis. Chest 1988; 94: 889-91.
20. SteinbachWJ, Benjamin DK Jr, Kontoyiannis DP et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-8.
21. Torres HA, Rivero GA, Lewis RE et al. Aspergillosis caused by nonfumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 2003; 46: 25-8.
22. Pfaller MA, Messer SA, Hollis RJ et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-7.
23. Sutton DA, Sanche SE, Revankar SG et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-5.
24. Blum G, Perkhofer S, Grif K et al. A 1-year Aspergillus terreus surveillance study at the University Hospital of Innsbruck: molecular typing of environmental and clinical isolates. Clin Microbiol Infect 2008; 14: 1146-51.
25. Ramos ER, Jiang Y, Hachem R et al. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist 2011; 16: 1049-60.
26. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
27. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH et al. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clinical Infect Dis 1998; 26: 1270-8.
28. Denning DW. Therapeutic outcome in invasive aspergillosis. Clinical Infect Dis 1996; 23: 608-15.
29. Hogan LH, Klein BS, Levitz SM. Virulence factors of medically important fungi. Clin Microbiol Rev 1996; 9: 469-88.
30. Auberger J, Lass-Florl C, Ulmer H et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2008; 88: 508-15.
31. Lass-Florl C. Aspergillus terreus: how inoculum size and host characteristics affect its virulence. J Infect Dis 2012; 205: 1192-4.
32. Slesiona S, Ibrahim-Granet O, Olias P et al. Murine infection models for Aspergillus terreus pulmonary aspergillosis reveal long-term persistence of conidia and liver degeneration. J Infect Dis 2012; 205: 1268-77.
33. Deak E, Wilson SD, White E et al. Aspergillus terreus accessory conidia are unique in surface architecture, cell wall composition and germination kinetics. PLoS One 2009; 4: e7673.
34. Deak E, Nelson M, Hernandez-Rodriguez Y et al. Aspergillus terreus accessory conidia are multinucleated, hyperpolarizing structures that display differential dectin staining and can induce heightened inflammatory responses in a pulmonary model of aspergillosis. Virulence 2011; 2: 200-7.
35. Slesiona S, Gressler M, Mihlan M et al. Persistence versus escape: Aspergillus terreus and Aspergillus fumigatus employ different strategies during interactions with macrophages. PLoS One 2012; 7: e31223.
36. Blum G, Hortnagl C, Jukic E et al. Newinsight into amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother 2013; 57: 1583-8.
37. Blum G, Kainzner B, Grif K et al. In vitro and in vivo role of heat shock protein 90 in amphotericin B resistance of Aspergillus terreus. Clin Microbiol Infect 2013; 19: 50-5.
38. Speth C, Blum G, Hagleitner M et al. Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility. Med Microbiol Immunol 2013; 202: 379-89.
39. Mortensen KL, Mellado E, Lass-Florl C et al. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents and Chemother 2010; 54: 4545-9.
40. Lockhart SR, Frade JP, Etienne KA et al. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents and Chemother 2011; 55: 4465-8.
41. Raad II, Chaftari AM, Al Shuaibi MM et al. Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications. Ann Oncol 2013; 24: 1873-9.